Nektar Therapeutics buy Rodman & Renshaw
Start price
28.06.24
/
50%
€1.19
Target price
28.06.25
€1.87
Performance (%)
-51.13%
End price
29.06.25
-
Summary
This prediction is currently being closed. Massive losses of -51.13% have been the result for the BUY prediction by Rodman___Renshaw. Rodman___Renshaw has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% |
Comments by Rodman___Renshaw for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $2.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von Rodman___Renshaw gewählte maximale Laufzeit wurde überschritten